全文获取类型
收费全文 | 580篇 |
免费 | 23篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 5篇 |
妇产科学 | 6篇 |
基础医学 | 57篇 |
口腔科学 | 48篇 |
临床医学 | 47篇 |
内科学 | 104篇 |
皮肤病学 | 18篇 |
神经病学 | 29篇 |
特种医学 | 16篇 |
外科学 | 95篇 |
综合类 | 8篇 |
预防医学 | 58篇 |
眼科学 | 14篇 |
药学 | 23篇 |
中国医学 | 3篇 |
肿瘤学 | 41篇 |
出版年
2024年 | 2篇 |
2023年 | 15篇 |
2022年 | 19篇 |
2021年 | 37篇 |
2020年 | 33篇 |
2019年 | 27篇 |
2018年 | 18篇 |
2017年 | 11篇 |
2016年 | 16篇 |
2015年 | 10篇 |
2014年 | 26篇 |
2013年 | 33篇 |
2012年 | 39篇 |
2011年 | 34篇 |
2010年 | 39篇 |
2009年 | 18篇 |
2008年 | 32篇 |
2007年 | 21篇 |
2006年 | 31篇 |
2005年 | 22篇 |
2004年 | 20篇 |
2003年 | 20篇 |
2002年 | 23篇 |
2001年 | 10篇 |
2000年 | 5篇 |
1999年 | 7篇 |
1998年 | 2篇 |
1997年 | 1篇 |
1996年 | 1篇 |
1995年 | 5篇 |
1992年 | 3篇 |
1991年 | 4篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1988年 | 4篇 |
1987年 | 2篇 |
1983年 | 2篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1978年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有603条查询结果,搜索用时 10 毫秒
1.
Emma J. Birks MRCP Magdi H. Yacoub DSc FRS Ani Anyanwu FRCS Rosemary Radley Smith FRCP Nicholas R. Banner FRCP Asghar Khaghani FRCS 《The Journal of heart and lung transplantation》2004,23(12):3688-1344
BACKGROUND: Transplantation for patients with a high pulmonary vascular resistance (PVR) carries an increased risk of mortality and right heart failure following heart transplantation and continues to be a major problem. We evaluated the use of hearts from patients who underwent heart and lung transplantation for primary pulmonary hypertension (PPH) as part of a domino procedure because these hearts have hypertrophied right ventricles used to increased pulmonary pressures, but could have a compromised left ventricle or irreversible damage of the right ventricle. METHODS: We reviewed 12 patients with PVR >4 Wood units who underwent orthotopic heart transplantation between 1989 and 1998 using hearts from donors with PPH as part of a domino procedure. RESULTS: We studied 10 men and 2 women, mean age 42.9 years. Mean PVR was 5.3 (range, 4-9) Wood units. Mean ischemia time was 85.3 minutes, and mean donor age was 32 years. Actuarial survival was 75% at 1 year and 75% at 5 years. In the early post-operative period, 3 patients had temporary arrhythmias, 2 required permanent pacemaker implantation, 1 had atrial fibrillation, and 1 had ventricular tachycardia that required defibrillator implantation. At a mean follow-up of 7.8 years, 2 patients had developed asymptomatic transplant coronary disease (both at 8.5 years after transplantation), 1 moderate and 1 very mild; the rest had none. Mean left ventricular ejection fraction at latest follow-up was 70.1% (range, 63%-78%). Right ventricular function assessed clinically and by echocardiography was adequate in the short and long term. CONCLUSIONS: Our results suggest that heart and lung recipients with PPH can provide useful donor hearts to patients with increased PVR and that these hearts function well in the intermediate and long term. 相似文献
2.
用BA-ELISA斑点法检测痢疾杆菌免疫小鼠GALT中的特异性抗体分泌细胞(ASC) 总被引:1,自引:0,他引:1
改进的BA-ELISPOT法使免疫酶斑更为清晰,保存时间延长。用此法检测了痢疾杆菌福氏2a经口及腹腔免疫后,小鼠派伊尔氏(PP)淋巴结、肠系膜淋巴结(MLN)及脾脏(SPL)中特异性IgA、IgG、IgM抗体分泌细胞(AntibodySecretingcell,ASC)的动态变化,得到有规律的结果:两种免疫途径均能在PP及MLN中诱导出3类特异ASC的显著升高,但口服导致的升高其持续时间较腹腔途径为短。此外,腹腔途径还能诱导SPL中3种ASC升高。 相似文献
3.
Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. 总被引:7,自引:0,他引:7
Sandra Gawchik Stanley Goldstein Bruce Prenner Ani John 《Annals of allergy, asthma & immunology》2003,90(4):416-421
BACKGROUND: Cough commonly occurs as a symptom of seasonal allergic rhinitis (SAR), an inflammatory condition of the nasal mucous membranes that results in rhinorrhea, nasal stuffiness/congestion, nasal itching, and sneezing. Mometasone furoate nasal spray (MFNS, Nasonex, Schering, Kenilworth, NJ), an anti-inflammatory nasal corticosteroid, has been shown to be safe and effective in reducing the nasal inflammation of SAR. OBJECTIVE: To examine the effectiveness of MFNS in relieving SAR-associated cough, in addition to nasal symptoms. METHODS: This was a multicenter, randomized, double-blind study. Patients 12 years of age or older with > or = 1-year history of SAR symptoms, positive skin test to a prevailing seasonal allergen, moderate nasal symptoms, and moderate cough were treated for 14 days with MFNS 200 microg daily (n = 122) or placebo (n = 123). RESULTS: The group treated with MFNS showed significant improvement in the daytime cough severity score at endpoint compared with placebo (P = 0.049). Improvement in the nighttime cough severity score showed a trend in favor of MFNS treatment. Treatment with MFNS significantly improved total nasal symptoms in both the daytime and nighttime compared with placebo at endpoint (P < or = 0.017). Overall daytime symptom scores (cough + total nasal) improved significantly compared with placebo at endpoint (P = 0.005). Overall nighttime symptom scores improved significantly compared with placebo at endpoint (P = 0.028). Treatments were well tolerated, with no significant differences in the incidence of adverse events. CONCLUSIONS: MFNS is effective and well tolerated in the treatment of daytime cough associated with SAR. 相似文献
4.
Evangelista André Nobre dos Santos Flávia Franciele de Oliveira Martins Lorena Pacheco Gaiad Thais Peixoto Machado Alex Sander Dias Rocha-Vieira Etel Costa Karine Beatriz Santos Ana Paula Oliveira Murilo Xavier 《Lasers in medical science》2021,36(6):1201-1208
Lasers in Medical Science - The aim of the present study was to investigate the effects of photobiomodulation (PBM) therapy on the expression of heat shock protein 70 (HSP70) and tissue repair in... 相似文献
5.
Sara Pilotto Antonio Rossi Tiziana Vavalà Alessandro Follador Marcello Tiseo Domenico Galetta Alessandro Morabito Massimo Di Maio Olga Martelli Orazio Caffo Pier Luigi Piovano Diego Cortinovis Nicoletta Zilembo Clelia Casartelli Giuseppe Luigi Banna Antonio Ardizzoia Maria Luisa Barzelloni Alessandra Bearz Silvia Novello 《Clinical lung cancer》2018,19(1):93-104
Background
Beyond progression after tyrosine kinase inhibitor in EGFR-positive non-small-cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study that reported the outcomes of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in a “real-life” Caucasian EGFR-mutated non-small-cell lung cancer (NSCLC) population. The sharing of multi-institutional experiences represents a crucial strategy to enrich knowledge about uncommon EGFR mutations. Therefore, we performed a post hoc analysis of the BE-POSITIVE study.Patients and Methods
Data of advanced NSCLC patients with uncommon EGFR mutations who received first-line first-generation EGFR-TKIs in 24 Italian Hospitals were collected. In this analysis we aimed to evaluate overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) of EGFR-TKIs in NSCLC patients harboring uncommon EGFR mutations.Results
Thirty-five patients harboring uncommon EGFR mutations (any mutation other than deletion 19 or substitution of leucine by arginine at codon 858) were included of the original 312 EGFR-mutated cases. Most of them were female (n = 20, 57.1%), former smokers (n = 23, 65.7%), with adenocarcinoma (n = 31, 88.6%). The most frequent EGFR mutations were G719X (n = 6, 17.2%) and L861Q (n = 5, 14.2%). The population presented an ORR of 25.7%, a median PFS of 5.19 months, and a median OS of 14.49 months. When stratified according to type of EGFR mutation, median OS ranged from 3.65 months for unspecified mutations to 21.29 for double EGFR mutations. Median PFS ranged from 1.77 months for unspecified mutations to 20.83 months for concomitant EGFR-anaplastic lymphoma kinase alteration. ORR varied from 0% in exon 18, 20 and double gene alteration to 66.6% in exon 19.Conclusion
Our study supports the existence of a strong outcome heterogeneity within patients harboring uncommon EGFR mutations, which needs to be clarified to achieve a real personalized treatment strategy. 相似文献6.
Mohammed Al Ani George Garas James Hollingshead Drostan Cheetham Thanos Athanasiou Vanash Patel 《Medical principles and practice》2022,31(4):342
The UK government had intended to introduce a comprehensive Electronic Health Record (EHR) system in England by 2020. These EHRs would run across primary, secondary, and social care, linking data in a single digital platform. The objectives of this systematic review were to identify studies that compare EHR in terms of direct comparison between systems and to evaluate them using System and Software Quality Requirements and Evaluation (SQuaRE) ISO/IEC 25010. A systematic review was performed by searching Embase and Ovid MEDLINE databases between 1974 and April 2021. All original studies that appraised EHR systems and their providers were included. The main outcome measures were EHR system comparison and the eight characteristics of SQuaRE: functional suitability, performance efficiency, compatibility, usability, reliability, security, maintainability, and portability. A total of 724 studies were identified using the search criteria. After a review of titles and abstracts, this was filtered down to 40 studies as per the exclusion and inclusion criteria set out in our study. Seven studies compared more than one EHR. The following number of studies looked at the various aspects of the SQuaRE, respectively − 19 studies: functional suitability, performance efficiency: 18 studies, compatibility: 12 studies, usability: 25 studies, reliability: 6 studies, security: 2 studies, maintainability: 16 studies, portability: 13 studies. Epic was the most studied EHR system and one of the most implemented systems in the US market and one of the top ten in the UK. It is difficult to assess which is the most advantageous EHR system when they are assessed by SQuaRE''s 8 characteristics for software evaluation. 相似文献
7.
Bassel El Zorkany Nizar Al Ani Samar Al Emadi Jamal Al Saleh Imad Uthman Yasser El Dershaby Mohamed Mounir Hani Al Moallim 《Clinical rheumatology》2018,37(5):1143-1152
The increasing availability of biosimilar medicines in Middle Eastern regions may provide an opportunity to increase the number of rheumatology patients who have access to traditionally more expensive biologic medicines. However, as well as a lack of real-world data on the use of biosimilar medicines in practice, the availability of intended copies in the region may undermine physician confidence in prescribing legitimate biosimilar medicines. There is a need for regional recommendations for healthcare professionals to ensure that biosimilar drugs can be used safely. Therefore, a literature search was performed with the aim of providing important recommendations for the regulation and use of biosimilar medicines in the Middle East from key opinion leaders in rheumatology from the region. These recommendations focus on improving the availability of relevant real-world data, ensuring that physicians are aware of the difference between intended copies and true biosimilars and ensuring that physicians are responsible for making any prescribing and switching decisions. 相似文献
8.
9.
Brkić Hrvoje Galić Ivan Vodanović Marin Dumančić Jelena Mehdi Fuad Anić Milošević Sandra 《International journal of legal medicine》2022,136(6):1685-1696
International Journal of Legal Medicine - This study aimed to evaluate the accuracy and precision of the Cameriere European formula, Demirjian, Haavikko, and Willems methods for estimating dental... 相似文献
10.
Ani Bilazarian 《Nursing forum》2021,56(1):127-133